New combo aims to keep advanced lung cancer in check
NCT ID NCT07141264
First seen Jan 09, 2026 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This study tests whether combining the immunotherapy drug adebrelimab with the chemotherapy drug etoposide can help control extensive-stage small cell lung cancer after initial treatment. About 32 adults in China will receive the combo as maintenance therapy until their cancer worsens. The goal is to see if it delays progression and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital Affiliated to the Fourth Military Medical University
RECRUITINGXi'an, Shannxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (an immunotherapy drug) combined with etoposide capsules (a chemotherapy drug)
What this could lead to
If successful, this combination could offer a new maintenance therapy option to help control extensive-stage small cell lung cancer and delay its progression.
What could go wrong
This is a small, early-phase (Phase 2) study with only 32 participants, so results may not apply broadly. The drugs can cause side effects, and the trial does not compare against a standard treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.